PROCEPT BioRobotics Corporation (PRCT)
NASDAQ: PRCT · Real-Time Price · USD
24.52
-1.15 (-4.48%)
At close: Apr 16, 2026, 4:00 PM EDT
24.39
-0.13 (-0.53%)
Pre-market: Apr 17, 2026, 4:00 AM EDT
PROCEPT BioRobotics Employees
PROCEPT BioRobotics had 888 employees as of December 31, 2025. The number of employees increased by 132 or 17.46% compared to the previous year.
Employees
888
Change (1Y)
132
Growth (1Y)
17.46%
Revenue / Employee
$346,908
Profits / Employee
-$107,626
Market Cap
1.38B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 888 | 132 | 17.46% |
| Dec 31, 2024 | 756 | 130 | 20.77% |
| Dec 31, 2023 | 626 | 198 | 46.26% |
| Dec 31, 2022 | 428 | 194 | 82.91% |
| Dec 31, 2021 | 234 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AdaptHealth | 10,900 |
| Enovis | 7,802 |
| UFP Technologies | 4,846 |
| CONMED | 3,900 |
| Tandem Diabetes Care | 2,500 |
| Avanos Medical | 2,287 |
| NovoCure | 1,605 |
| Inspire Medical Systems | 1,333 |
PRCT News
- 7 days ago - PROCEPT BioRobotics® to Report First Quarter 2026 Financial Results on April 29, 2026 - GlobeNewsWire
- 24 days ago - EAU Guidelines Upgrade Aquablation® Therapy to Strong Surgical Recommendation for BPH - GlobeNewsWire
- 5 weeks ago - PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy - GlobeNewsWire
- 5 weeks ago - PRCT Investors Have Opportunity to Join PROCEPT BioRobotics Corporation Fraud Investigation with the Schall Law Firm - Business Wire
- 7 weeks ago - Ademi LLP Investigates Claims of Securities Fraud against PROCEPT BioRobotics Corporation - PRNewsWire
- 7 weeks ago - PROCEPT BioRobotics® Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth - GlobeNewsWire
- 7 weeks ago - PROCEPT BioRobotics Stock Hits 52-Week Low - Here's Why - Benzinga
- 7 weeks ago - PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance - GlobeNewsWire